for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mylan NV

MYL.O

Latest Trade

21.00USD

Change

0.00(0.00%)

Volume

9,182,651

Today's Range

20.60

 - 

21.39

52 Week Range

16.63

 - 

39.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
21.00
Open
20.61
Volume
9,182,651
3M AVG Volume
153.13
Today's High
21.39
Today's Low
20.60
52 Week High
39.59
52 Week Low
16.63
Shares Out (MIL)
515.87
Market Cap (MIL)
10,982.87
Forward P/E
4.94
Dividend (Yield %)
--

Next Event

Q3 2019 Mylan NV Earnings Release

Latest Developments

More

Mylan Expands Oncology Portfolio With Launch Of Generic Faslodex Injection

Revance Therapeutics Inc - Co & Mylan Ireland Amended Collaboration & License Agreement Dated Feb 28, 2018

Mylan NV Says Director Robert Coury Reports Open Market Purchase Of 49,859 Ordinary Shares At Average Price Of $20.06Per Share On August 2

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mylan NV

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.

Industry

Biotechnology & Drugs

Contact Info

Unit 4, Trident Place, Mosquito Way

+44.1707.853000

https://www.mylan.com

Executive Leadership

Robert J. Coury

Non-Executive Chairman of the Board

Rajiv Malik

President, Executive Director

Heather M. Bresch

Chief Executive Officer, Executive Director

Mark W. Parrish

Lead Independent Non-Executive Vice Chairman of the Board

Kenneth Scott Parks

Chief Financial Officer

Key Stats

1.94 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

11.1K

2017

11.9K

2018

11.4K

2019(E)

11.6K
EPS (USD)

2016

4.890

2017

4.560

2018

4.580

2019(E)

4.306
Price To Earnings (TTM)
563.97
Price To Sales (TTM)
0.97
Price To Book (MRQ)
0.92
Price To Cash Flow (TTM)
5.55
Total Debt To Equity (MRQ)
111.66
LT Debt To Equity (MRQ)
105.77
Return on Investment (TTM)
0.07
Return on Equity (TTM)
0.06

Latest News

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta.

Denmark's Novo Nordisk files lawsuit against Mylan over patent

Novo Nordisk <NOVOb.CO> said on Thursday it has filed litigation in a Delaware district court against Mylan <MYL.O> aimed at blocking its attempt to market a generic version of the Danish insulin maker's drug Victoza.

Teva to launch generic version of EpiPen for young children

Teva Pharmaceutical Industries Ltd said on Tuesday its generic version of Mylan's EpiPen for young children will be available in most retail pharmacies at a price of $300 for a 2-pack.

UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis

The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said on Wednesday.

U.S. lawmakers push Mylan, Teva over drug pricing probe

The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

U.S. lawmakers push Mylan, Teva over drug pricing probe -statement

The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe.

Mylan CEO must sit for new EpiPen litigation deposition - judge

Lawyers for consumers who claim Mylan NV schemed to squelch competition for its EpiPen device may depose its chief executive again after obtaining documents from a company they say agreed to delay the release of a generic version of the emergency allergy treatment.

Mylan reaches $30 million settlement in SEC's EpiPen probe

Mylan NV has reached a tentative agreement to pay $30 million to resolve a probe by the U.S. Securities and Exchange Commission related to its emergency allergy shot EpiPen, which became the center of a firestorm over price increases.

Celgene to pay Mylan $62 million to resolve cancer drug antitrust case

Mylan NV says Celgene Corp will pay it $62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

RPT-GRAPHIC-Mylan stock boost follows long share struggles for company, generics industry

Shares of Mylan NV surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc's off-patent branded drugs business. But in the bigger picture, the surge is lost in a bleaker landscape for Mylan's stock price and the broader generic drug industry since...

Mylan deal puts future of its beleaguered EpiPen in spotlight

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Mylan stock boost follows long share struggles for company, generics industry

Shares of Mylan NV <MYL.O> surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc's <PFE.N> off-patent branded drugs business. But in the bigger picture, the surge is lost in a bleaker landscape for Mylan's stock price and the broader generic drug...

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc <PFE.N> has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV <MYL.O>, a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Pfizer in talks to transition EpiPen manufacturing into generics spinoff

Pfizer Inc is in talks to merge its contract manufacturer that produces Mylan's EpiPen emergency allergy treatment into the new generics business it has created by combining its older off-patent medicines unit with generic drugmaker Mylan NV, a Pfizer spokeswoman said.

Mylan to combine with Pfizer's off-patent medicines unit

Mylan NV said on Monday it would combine with Pfizer Inc's off-patent branded and generic established medicines business to form a global generic drugmaker.

Pfizer in talks to merge off-patent drugs business with Mylan: source

Pfizer Inc <PFE.N> is in talks to merge its off-patent drugs business with Mylan NV <MYL.O> in a stock deal, according to a source familiar with the matter.

Pfizer in talks to merge off-patent drugs business with Mylan

Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Novartis to sell epinephrine shot in U.S. pharmacies amid EpiPen shortage

Novartis AG <NOVN.S> said on Tuesday it would make its generic pre-filled epinephrine shots immediately available in local pharmacies across the United States, as a shortage of Mylan NV's <MYL.O> EpiPen emergency allergy treatment drags on due to manufacturing problems.

Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage

A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen.

Mylan seeks dismissal of Sanofi's EpiPen antitrust lawsuit

Mylan Plc is urging a federal judge to reject rival drugmaker Sanofi SA's claims the company engaged in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a political firestorm over price increases.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up